	Application No.	A U WAY
	Application No.	Applicant(s)
Notice of Allowability	10/601,314	ZHAO ET AL.
	Examiner	Art Unit
	Bernard Dentz	1625
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Amdt.of 5-30-2006</u> .		
2. The allowed claim(s) is/are 75-147.		
3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☑ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	·	
Attachment(a)		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) →	5 D Notice of Informal P	atent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	(PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08	Paper No./Mail Dat B), 7. ⊠ Examiner's Amendr	re nent/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	_	ent of Reasons for Allowance
of Biological Material	9.	issue is in mornality
•	J	
•		
	•	

Application/Control Number: 10/601,314

Art Unit: 1625

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Huleat on 8-2-2006.

Claim 81, line 2; claim 86, line 3; claim 115, line 2 and claim 125, line 2 before "sustained-release" - - or - - has been inserted.

Claim 81, line 2; claim 86, line 3; claim 115, line 2 and claim 125, line 2 after "sustained-release" "or" has been deleted.

Claim 91, line 2 "is" has been canceled.

Claim 106, line 2 "comprising" has been changed to - -comprises- -.

Claim 141, line 3 "an" has been changed to - -a therapeutically effective- -.

The following is an examiner's statement of reasons for allowance: In reviewing the art and the rejections in the last Office Action the Examiner has concluded that it would not have been obvious to one of ordinary skill in the art that the instant compositions consisting essentially of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate would reduce low density lipoprotein (LDL) while not significantly reducing high density lipoprotein (HDL) in a human subject. Of course the language of the claims and the whole tenor of the disclosure distinguishes applicants' useful composition from black tea.

Application/Control Number: 10/601,314

Art Unit: 1625

Page 3

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas McKenzie, can be reached on 571 272-0670. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz

8-2-2006

BERNARD DENTZ